EHA 2025 | Combination strategies under investigation in myelofibrosis and their use in the frontline setting

So as is true for most cancers I think myelofibrosis is going to be a disease that will need to be treated as a combination for most patients at least at some point in their treatment and presumably front line for most patients. And there are a lot of exciting drugs that are in development in this setting to treat myelofibrosis patients in combination mostly with ruxolitinib but with other JAK inhibitors as well. And usually these trials start as a sort of second or third line setting and relapsed refractory setting but eventually move to the front line. So I think most of us were hoping that we would have more of these drugs available already but so far that has not happened, but I think there’s still hope that as these new drugs are going through phase three trials and as more data is being gathered, that we’ll have these drugs be available to patients. So some of the examples, there are many, many drugs in development. I’m not going to mention them all, but I think some of the development, some of the drugs that I am excited about and hopefully we’ll see more data and be able to really learn more about these drugs and combinations, drugs like selinexor, pelabresib, navtemadlin, as well as imetelstat. I mean, these studies are ongoing, both in the sort of second, third-line setting, as well as in the frontline setting. And as we get more results, I think we’ll have a better idea of, you know which drugs will move forward to you know hopefully to approval and and become available in a first-line setting.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.